Show simple item record

dc.contributor.authorMoore, James V
dc.contributor.authorWaller, Michael L
dc.contributor.authorZhao, Sha
dc.contributor.authorDodd, Nicholas J F
dc.contributor.authorActon, P D
dc.contributor.authorJeavons, A P
dc.contributor.authorHastings, D L
dc.date.accessioned2010-02-12T16:01:43Z
dc.date.available2010-02-12T16:01:43Z
dc.date.issued1998-09
dc.identifier.citationFeasibility of imaging photodynamic injury to tumours by high-resolution positron emission tomography. 1998, 25 (9):1248-54 Eur J Nucl Meden
dc.identifier.issn0340-6997
dc.identifier.pmid9724373
dc.identifier.doi10.1007/s002590050292
dc.identifier.urihttp://hdl.handle.net/10541/92011
dc.description.abstractOne early effect of the treatment of tumours by the new modality photodynamic therapy (PDT) is a reduction in tumour glucose levels. We have employed the widely used positron-emitting glucose analogue flurorine-18 fluoro-2-deoxy-D-glucose ([18F]-FDG), to determine whether, in principle, PDT-induced injury might be delineated non-invasively and quantitatively by positron emission tomography (PET). The scanner was of the high-density avalanche-chamber (HIDAC) type with a resolution of 2.6 mm. Subcutaneous T50/80 mouse mammary tumours, sensitised by haematoporphyrin ester, were illuminated by graded doses of interstitial 630 nm light. Thirty hours later, any remaining viable tumour was detected (a) by region-of-interest analysis of the PET images and (b) by gamma counting the excised tumour. PET measurements of % uptake of [18F]-FDG into tumour correlated closely with ex vivo gamma counting (slope=0.976, r2=0. 995), validating the in situ method. Uptake into untreated, control tumours was 3.8%+/-1.1% of the injected activity. Uptake of [18F]-FDG into treated tumours decreased by 0.7% for every 100 mm3 reduction in remaining viable histological volume. Outcome was further compared with that measured by (a) T2-weighted proton imaging on a 4.7-T magnetic resonance imaging (MRI) system and (b) histological analysis of subsequently sectioned tumours. PET using [18F]-FDG described the absolute volume of surviving tumour histological mass to the same degree as high-resolution MRI. The conclusion of these initial studies is that PET with [18F]-FDG, although non-specific, quantitatively described at early times the extent of tumour destruction by PDT.
dc.language.isoenen
dc.subjectHaematoporphyrin Photoradiationen
dc.subject.meshAnimals
dc.subject.meshFeasibility Studies
dc.subject.meshFemale
dc.subject.meshFluorine Radioisotopes
dc.subject.meshFluorodeoxyglucose F18
dc.subject.meshHematoporphyrin Photoradiation
dc.subject.meshMagnetic Resonance Imaging
dc.subject.meshMammary Neoplasms, Experimental
dc.subject.meshMice
dc.subject.meshMice, Nude
dc.subject.meshRadiopharmaceuticals
dc.subject.meshTomography, Emission-Computed
dc.titleFeasibility of imaging photodynamic injury to tumours by high-resolution positron emission tomography.en
dc.typeArticleen
dc.contributor.departmentPaterson Institute for Cancer Research, Christie Hospital (NHS) Trust, Manchester, UK.en
dc.identifier.journalEuropean Journal of Nuclear Medicineen
html.description.abstractOne early effect of the treatment of tumours by the new modality photodynamic therapy (PDT) is a reduction in tumour glucose levels. We have employed the widely used positron-emitting glucose analogue flurorine-18 fluoro-2-deoxy-D-glucose ([18F]-FDG), to determine whether, in principle, PDT-induced injury might be delineated non-invasively and quantitatively by positron emission tomography (PET). The scanner was of the high-density avalanche-chamber (HIDAC) type with a resolution of 2.6 mm. Subcutaneous T50/80 mouse mammary tumours, sensitised by haematoporphyrin ester, were illuminated by graded doses of interstitial 630 nm light. Thirty hours later, any remaining viable tumour was detected (a) by region-of-interest analysis of the PET images and (b) by gamma counting the excised tumour. PET measurements of % uptake of [18F]-FDG into tumour correlated closely with ex vivo gamma counting (slope=0.976, r2=0. 995), validating the in situ method. Uptake into untreated, control tumours was 3.8%+/-1.1% of the injected activity. Uptake of [18F]-FDG into treated tumours decreased by 0.7% for every 100 mm3 reduction in remaining viable histological volume. Outcome was further compared with that measured by (a) T2-weighted proton imaging on a 4.7-T magnetic resonance imaging (MRI) system and (b) histological analysis of subsequently sectioned tumours. PET using [18F]-FDG described the absolute volume of surviving tumour histological mass to the same degree as high-resolution MRI. The conclusion of these initial studies is that PET with [18F]-FDG, although non-specific, quantitatively described at early times the extent of tumour destruction by PDT.


This item appears in the following Collection(s)

Show simple item record